Health & Fitness
Mon, August 6, 2012Fri, August 3, 2012Thu, August 2, 2012Wed, August 1, 2012Tue, July 31, 2012Mon, July 30, 2012Sun, July 29, 2012Fri, July 27, 2012Thu, July 26, 2012Wed, July 25, 2012Tue, July 24, 2012Mon, July 23, 2012Sun, July 22, 2012Sat, July 21, 2012Fri, July 20, 2012Thu, July 19, 2012Wed, July 18, 2012Tue, July 17, 2012Mon, July 16, 2012Fri, July 13, 2012Thu, July 12, 2012Wed, July 11, 2012Tue, July 10, 2012Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
//health-fitness.news-articles.net/content/2012/ .. mpletion-of-public-offering-of-common-stock.html
Published in Health and Fitness on Tuesday, July 24th 2012 at 13:37 GMT by Market Wireš This publication is a summary or evaluation of another publication
Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of... -- HAYWARD, Calif., July 24, 2012 /PRNewswire/ --
Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
HAYWARD, Calif., July 24, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: [ ANTH ]), today announced that it has completed the previously announced underwritten public offering of 33,000,000 shares of its common stock, offered at a price to the public of $1.00 per share. In addition, the Company has sold 4,950,000 shares of its common stock at a price to the public of $1.00 per share pursuant to the underwriters' option to purchase additional shares, resulting in a total public offering of 37,950,000 shares. The gross proceeds to the Company from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were $37,950,000. Anthera intends to use the net proceeds from this offering for general corporate purposes.
Piper Jaffray& Co. and Leerink Swann LLC acted as joint book-running managers in the offering. Canaccord Genuity acted as lead manager in the offering. Summer Street Research Partners acted as co-manager in the offering.
The securities described above were offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at [ http://www.sec.gov ]. Copies of the final prospectus supplement relating to these securities may be obtained from Piper Jaffray& Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at [ prospectus@pjc.com ], or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by telephone at 800-808-7525 or by email at [ Syndicate@Leerink.com ].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to the anticipated use of proceeds from the offering. Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to the risks and uncertainties set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2012. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., [ bnery@anthera.com ] or 510.856.5586.
SOURCE Anthera Pharmaceuticals, Inc.
[ Back to top ]
RELATED LINKS
[ http://www.anthera.com ]
